Investors might be losing patience for Apellis Pharmaceuticals' (NASDAQ:APLS) increasing losses, as stock sheds 6.3% over the past week

Despite recent stock price decline, Apellis Pharmaceuticals has shown strong revenue growth of 48% per year over the last 5 years. While short-term shareholders faced losses, long-term investors gained 11% annually. Analysts recommend monitoring the company's performance for potential investment opportunities.